Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CD44 | P16070 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31723224 | 1.00 | HSD17B1 (0.34) | HSD17B1HSD17B2ACHECD44CYP3A4 | |
| SCHEMBL29454101 | 1.00 | HSD17B1 (0.34) | HSD17B1HSD17B2ACHECD44CYP3A4 | |
| SCHEMBL22232035 | 0.82 | CD44 (0.32) | CD44CYP3A4TSHRPIK3CA | |
| SCHEMBL31723190 | 0.82 | CD44 (0.32) | CD44CYP3A4TSHRPIK3CA | |
| SCHEMBL29454137 | 0.82 | CD44 (0.32) | CD44CYP3A4TSHRPIK3CA | |
| SCHEMBL28925354 | 0.80 | HSD17B1 (0.34) | HSD17B1HSD17B2ACHE | |
| SCHEMBL22232350 | 0.77 | ABCG2 (0.38) | ACHEDHFR | |
| SCHEMBL29454066 | 0.77 | ABCG2 (0.38) | ACHEDHFR | |
| SCHEMBL31723221 | 0.77 | ABCG2 (0.38) | ACHEDHFR | |
| SCHEMBL31723210 | 0.76 | CHKA (0.37) | CYP3A4DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089523-A1 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | PI INDUSTRIES LTD. (IN) | 2022-03-24 | — | — | US | claimed |
| EP-3911629-A1 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | PI Industries Ltd. (IN) | 2021-11-24 | — | — | EP | claimed |
| WO-2020148617-A1 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | PI INDUSTRIES LTD. (IN) | 2020-07-23 | — | — | WO | claimed |
| US-20220089523-A1 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | PI INDUSTRIES LTD. (IN) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089523-A1 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | H1-3, PRMT7, PFAS | HSD17B1 4672/4885HSD17B2 4732/4885ACHE 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.